GlassScriptPhysician profile
Zainab Savard
NPI 1003565003
$1,841.00
in general payments reported to CMS, 2019-2025
18 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $61.99 · 2024: $451 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.00 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $432.22 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $272.85 | 2023-2025 | Spravato |
| Abbvie INC. | $257.27 | 2024-2025 | |
| Neuronetics, INC. | $152.38 | 2024 | Neurostar Tms Therapy System |
| Neurocrine Biosciences, INC. | $151.85 | 2025 | |
| Janssen Scientific Affairs, LLC | $133.08 | 2023-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $57.99 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $50.51 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $49.10 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $47.36 | 2023-2025 | |
| Alkermes, INC. | $44.46 | 2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $44.30 | 2025 | Qelbree |
| Lundbeck LLC | $42.99 | 2025 | Rexulti |
| Corium, LLC | $28.82 | 2025 | Azstarys |
| Almatica Pharma LLC | $23.27 | 2025 | Loreev Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $22.08 | 2025 | Aplenzin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.42 | 2024 | Caplyta |
| Collegium Pharmaceutical, INC. | $15.05 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zainab Savard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.